Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy


You May Also Like

II-VI Incorporated Launches Ultraviolet Fluorescence Filters for Biomedical Instruments  

PITTSBURGH, Jan. 17, 2018 (GLOBE NEWSWIRE) -- II‐VI Incorporated (NASDAQ:IIVI), a leading provider of ...

FIT Biotech Oy: FIT Biotech’s company site has been launched in

FIT Biotech Oy                                                                   Press Release July 4th, 2018, 09.30 EET FIT Biotech's company site ...